NDT Advance Access originally published online on August 25, 2007
Nephrology Dialysis Transplantation 2007 22(12):3679; doi:10.1093/ndt/gfm539
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Serum phosphorus and the risk of progression of chronic kidney disease
Email: csaba.kovesdy{at}med.va.govSir,
We read with interest the recent paper by Voormolen et al. [1], describing an association between higher serum phosphorus levels and faster decline in renal function, in 432 patients with advanced chronic kidney disease (CKD). The authors contend that their study is the first to describe such an association in a large number of pre-dialysis CKD patients. We would like to direct the authors’ attention to two other papers, published last year and examining the same issue. We studied the association between serum phosphorus level and the incidence of dialysis or doubling of serum creatinine in 985 male patients (mostly CKD stages 3–4) [2]. We found that higher phosphorus was associated with a higher incidence of the renal end-point, even after adjustment for a number of potential confounders; a 1 mg/dl higher serum phosphorus level was associated with an adjusted hazard ratio (95% confidence interval) of 1.29 (1.12–1.48, P < 0.001) for the composite renal end-point. Another study examined risk factors for progression of CKD in 1094 black patients, enrolled in the African American Study of Hypertension and Kidney Disease (AASK) and, while serum phosphorus level was not its main focus, it also found serum phosphorus level to be one of the several independent predictors of progressive CKD [3]. The results presented by Voormolen et al. are certainly concordant with those described in these earlier studies and should form the basis for future trials examining the impact that lowering of serum phosphorus might have on progression of CKD.
Conflict of interest statement. None declared.
1Salem VA Medical Center
Salem, VA, USA
2Harbor-UCLA
Torrance, CA, USA
Notes
Note: Dr Voormolen et al. were invited to provide a reply, but we did not receive a response.
References
- Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant (2007).
- Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol (2006) 1:825–831.
[Abstract/Free Full Text] - Norris KC, Greene T, Kopple J, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol (2006) 17:2928–2936.
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Jamal, D. Fitchett, C. E. Lok, D. C. Mendelssohn, and R. T. Tsuyuki The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3168 - 3174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Foley Phosphate Levels and Cardiovascular Disease in the General Population Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1136 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Regidor, C. P. Kovesdy, R. Mehrotra, M. Rambod, J. Jing, C. J. McAllister, D. Van Wyck, J. D. Kopple, and K. Kalantar-Zadeh Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2193 - 2203. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||